UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.

The online employee and further education provider has listed on TSE’s Mothers Market, allowing Tokyo Institute of Technology to exit.

CAS-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.

Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.